Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevacizumab (Mabscale)
- Development stage
- Unknown
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Bevacizumab (Mabscale) is a biosimilar version of the reference monoclonal antibody Avastin, developed by the Russian biotechnology company Mabscale, LLC. It is a recombinant humanized IgG1 monoclonal antibody that targets and neutralizes vascular endothelial growth factor A (VEGF-A). By binding to VEGF-A, the drug prevents its interaction with VEGFR-1 and VEGFR-2 receptors on endothelial cells, thereby inhibiting the signaling pathways that drive tumor angiogenesis, vessel permeability, and tumor growth. This biosimilar is currently being evaluated in a Phase III clinical trial (BEV-III/2022) as a first-line treatment for patients with advanced, unresectable, or metastatic non-squamous non-small cell lung cancer (NSCLC), administered in combination with paclitaxel and carboplatin to demonstrate therapeutic equivalence to the originator product.
- Other names
- bevacizumab biosimilar (Mabscale)Mabscale bevacizumab
02
Targets
Beyond the preview
Go deeper on bevacizumab (Mabscale).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevacizumab (Mabscale).